GSK2879552
200200
Phase 1 small_molecule terminated
Quick answer
GSK2879552 for Leukaemia, Myelocytic, Acute is a Phase 1 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Leukaemia, Myelocytic, Acute
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated